0001104659-21-154717.txt : 20211230 0001104659-21-154717.hdr.sgml : 20211230 20211230162315 ACCESSION NUMBER: 0001104659-21-154717 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20211230 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211230 DATE AS OF CHANGE: 20211230 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MAGELLAN HEALTH INC CENTRAL INDEX KEY: 0000019411 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOSPITALS [8060] IRS NUMBER: 581076937 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-06639 FILM NUMBER: 211533097 BUSINESS ADDRESS: STREET 1: 4801 E. WASHINGTON ST CITY: PHOENIX STATE: AZ ZIP: 85034 BUSINESS PHONE: 800-642-1716 MAIL ADDRESS: STREET 1: 4801 E. WASHINGTON ST CITY: PHOENIX STATE: AZ ZIP: 85034 FORMER COMPANY: FORMER CONFORMED NAME: MAGELLAN HEALTH SERVICES INC DATE OF NAME CHANGE: 19960226 FORMER COMPANY: FORMER CONFORMED NAME: CHARTER MEDICAL CORP DATE OF NAME CHANGE: 19920703 8-K 1 tm2136427d1_8k.htm FORM 8-K
0000019411 false 0000019411 2021-12-30 2021-12-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 30, 2021

 

Magellan Health, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

1-6639

58-1076937 

(State or Other Jurisdiction

of Incorporation)

(Commission File

Number)

(IRS Employer

Identification No.)

  

4801 E. Washington Street

Phoenix, Arizona  

85034
(Address of Principal Executive Offices) (Zip Code)

   

Registrant's telephone number, including area code: (800) 642-1716

(Former Name or Former Address, if Changed Since Last Report): N/A

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.01 per share MGLN The NASDAQ Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

  

 

 

 

 

 

Item 8.01. Other Events.

 

On December 30, 2021, Magellan Health, Inc., a Delaware corporation (“Magellan”), and Centene Corporation, a Delaware corporation (“Centene”), announced that they have obtained all required regulatory approvals necessary to close Centene’s pending acquisition of Magellan. Subject to the satisfaction of customary closing deliveries, Magellan and Centene anticipate closing the acquisition on or about January 4, 2022.

 

A copy of the press release relating to the above issued by Magellan and Centene on December 30, 2021 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit

No. Description
   
99.1 Press Release, dated December 30, 2021.
   
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

  

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: December 30, 2021   MAGELLAN HEALTH, INC.
         
    By: /s/ David Haddock
      Name: David Haddock
      Title: General Counsel and Secretary

 

  

 

EX-99.1 2 tm2136427d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

N E W S   R E L E A S E  

 

Contacts: Media Investors  
  Marcela Manjarrez-Hawn Jennifer Lynch Gilligan  
  (314) 445-0790 (212) 759-0382  
  mediainquiries@centene.com investors@centene.com  

 

Centene and Magellan Satisfy All Regulatory Approvals

for Completion of Acquisition Agreement

 

ST. LOUIS (December 30, 2021)Centene Corporation (NYSE: CNC) and Magellan Health, Inc. (NASDAQ: MGLN) today announced that they have obtained all required regulatory approvals necessary to close Centene’s pending acquisition of Magellan Health. Subject to the satisfaction of customary closing deliveries, the parties anticipate closing the acquisition on or about January 4, 2022.

 

The agreement enables Centene to provide whole-health solutions across physical and mental health to deliver better health outcomes at lower costs for complex, high-cost populations.

 

“We are pleased to achieve this regulatory milestone, and we look forward to a timely close of the transaction. Our combined company will have expanded reach in a variety of specialty services and will provide increased access to behavioral healthcare during a time of need for the communities we serve,” said Michael Neidorff, Chairman and Chief Executive Officer of Centene.

 

About Centene Corporation

 

Centene Corporation, a Fortune 25 company, is a leading multi-national healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach – with local brands and local teams – to provide fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Centene offers affordable and high-quality products to nearly 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace, the TRICARE program, and individuals in correctional facilities. The Company also serves several international markets, and contracts with other healthcare and commercial organizations to provide a variety of specialty services focused on treating the whole person. Centene focuses on long-term growth and the development of its people, systems and capabilities so that it can better serve its members, providers, local communities, and government partners.Centene uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene's investor relations website, http://investors.centene.com/.

 

 

 

 

Forward-Looking Statements

 

All statements, other than statements of current or historical fact, contained in this press release are forward-looking statements. Without limiting the foregoing, forward-looking statements often use words such as "believe," "anticipate," "plan," "expect," "estimate," "intend," "seek," "target," "goal," "may," "will," "would," "could," "should," "can," "continue" and other similar words or expressions (and the negative thereof). Centene (the Company, our, or we) intends such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we are including this statement for purposes of complying with these safe-harbor provisions. In particular, these statements include, without limitation, statements about our future operating or financial performance, market opportunity, growth strategy, competition, expected activities in completed and future acquisitions, including statements about the impact of our proposed acquisition of Magellan Health (the Magellan Acquisition), our completed acquisition of WellCare Health Plans, Inc. (WellCare and such acquisition, the WellCare Acquisition), other recent and future acquisitions, investments, and the adequacy of our available cash resources. These forward-looking statements reflect our current views with respect to future events and are based on numerous assumptions and assessments made by us in light of our experience and perception of historical trends, current conditions, business strategies, operating environments, future developments and other factors we believe appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties and are subject to change because they relate to events and depend on circumstances that will occur in the future, including economic, regulatory, competitive and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions. All forward-looking statements included in this press release are based on information available to us on the date hereof. Except as may be otherwise required by law, we undertake no obligation to update or revise the forward-looking statements included in this press release, whether as a result of new information, future events or otherwise, after the date hereof. You should not place undue reliance on any forward-looking statements, as actual results may differ materially from projections, estimates, or other forward-looking statements due to a variety of important factors, variables and events including, but not limited to: the impact of COVID-19 on global markets, economic conditions, the healthcare industry and our results of operations and the response by governments and other third parties; our ability to accurately predict and effectively manage health benefits and other operating expenses and reserves, including fluctuations in medical utilization rates due to the impact of COVID-19; the risk that regulatory or other approvals required for the Magellan Acquisition may be delayed or not obtained or are subject to unanticipated conditions that could require the exertion of management's time and our resources or otherwise have an adverse effect on us; the possibility that certain conditions to the consummation of the Magellan Acquisition will not be satisfied or completed on a timely basis and accordingly, the Magellan Acquisition may not be consummated on a timely basis or at all; uncertainty as to the expected financial performance of the combined company following completion of the Magellan Acquisition; the possibility that the expected synergies and value creation from the Magellan Acquisition or the WellCare Acquisition (or other acquired businesses) will not be realized, or will not be realized within the respective expected time periods; the risk that unexpected costs will be incurred in connection with the completion and/or integration of the Magellan Acquisition or that the integration of Magellan Health will be more difficult or time consuming than expected, or similar risks from other acquisitions we may announce or complete from time to time; the risk that potential litigation in connection with the Magellan Acquisition may affect the timing or occurrence of the Magellan Acquisition or result in significant costs of defense, indemnification and liability; disruption from the announcement, pendency, completion and/or integration of the Magellan Acquisition or from the integration of the WellCare Acquisition, or similar risks from other acquisitions we may announce or complete from time to time, including potential adverse reactions or changes to business relationships with customers, employees, suppliers or regulators, making it more difficult to maintain business and operational relationships; a downgrade of the credit rating of our indebtedness; the inability to retain key personnel; competition; membership and revenue declines or unexpected trends; changes in healthcare practices, new technologies and advances in medicine; increased healthcare costs; changes in economic, political or market conditions; changes in federal or state laws or regulations, including changes with respect to income tax reform or government healthcare programs as well as changes with respect to the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act (collectively referred to as the ACA) and any regulations enacted thereunder that may result from changing political conditions, the new administration or judicial actions; rate cuts or other payment reductions or delays by governmental payors and other risks and uncertainties affecting our government businesses; our ability to adequately price products; tax matters; disasters or major epidemics; changes in expected contract start dates; provider, state, federal, foreign and other contract changes and timing of regulatory approval of contracts; the expiration, suspension, or termination of our contracts with federal or state governments (including, but not limited to, Medicaid, Medicare, TRICARE or other customers); the difficulty of predicting the timing or outcome of legal or regulatory proceedings or matters, including, but not limited to, our ability to resolve claims and/or allegations made by states with regard to past practices, including at Envolve Pharmacy Solutions, Inc. (Envolve), as our pharmacy benefits manager (PBM) subsidiary, within the reserve estimate we have recorded and on other acceptable terms, or at all, or whether additional claims, reviews or investigations relating to our PBM business will be brought by states, the federal government or shareholder litigants, or government investigations; timing and extent of benefits from strategic value creation initiatives; challenges to our contract awards; cyber-attacks or other privacy or data security incidents; the exertion of management's time and our resources, and other expenses incurred and business changes required in connection with complying with the undertakings in connection with any regulatory, governmental or third party consents or approvals for acquisitions, including the Magellan Acquisition; changes in expected closing dates, estimated purchase price and accretion for acquisitions; the risk that acquired businesses will not be integrated successfully; restrictions and limitations in connection with our indebtedness; our ability to maintain or achieve improvement in the Centers for Medicare and Medicaid Services (CMS) Star ratings and maintain or achieve improvement in other quality scores in each case that can impact revenue and future growth; availability of debt and equity financing, on terms that are favorable to us; inflation; foreign currency fluctuations and risks and uncertainties discussed in the reports that Centene has filed with the Securities and Exchange Commission. This list of important factors is not intended to be exhaustive. We discuss certain of these matters more fully, as well as certain other factors that may affect our business operations, financial condition and results of operations, in our filings with the Securities and Exchange Commission (SEC), including our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Due to these important factors and risks, we cannot give assurances with respect to our future performance, including without limitation our ability to maintain adequate premium levels or our ability to control our future medical and selling, general and administrative costs.

 

 

 

EX-101.SCH 3 mgln-20211230.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 mgln-20211230_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 mgln-20211230_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2136427d1_ex99-1img001.jpg GRAPHIC begin 644 tm2136427d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.4
Cover
Dec. 30, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 30, 2021
Entity File Number 1-6639
Entity Registrant Name Magellan Health, Inc.
Entity Central Index Key 0000019411
Entity Tax Identification Number 58-1076937
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 4801 E. Washington Street
Entity Address, City or Town Phoenix
Entity Address, State or Province AZ
Entity Address, Postal Zip Code 85034
City Area Code 800
Local Phone Number 642-1716
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol MGLN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2136427d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000019411 2021-12-30 2021-12-30 iso4217:USD shares iso4217:USD shares 0000019411 false 8-K 2021-12-30 Magellan Health, Inc. DE 1-6639 58-1076937 4801 E. Washington Street Phoenix AZ 85034 800 642-1716 false false false false Common Stock, par value $0.01 per share MGLN NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.4 html 1 118 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://magellanhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2136427d1_8k.htm mgln-20211230.xsd mgln-20211230_lab.xml mgln-20211230_pre.xml tm2136427d1_ex99-1.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2136427d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2136427d1_8k.htm" ] }, "labelLink": { "local": [ "mgln-20211230_lab.xml" ] }, "presentationLink": { "local": [ "mgln-20211230_pre.xml" ] }, "schema": { "local": [ "mgln-20211230.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "mgln", "nsuri": "http://magellanhealth.com/20211230", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2136427d1_8k.htm", "contextRef": "From2021-12-30to2021-12-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://magellanhealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2136427d1_8k.htm", "contextRef": "From2021-12-30to2021-12-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://magellanhealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-21-154717-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-154717-xbrl.zip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end